Verici Dx said its Tutivia lab-developed kidney transplant rejection risk test received approval from New York State’s Clinical Laboratory Evaluation Program, enabling nationwide availability. Tutivia uses a 17-gene mRNA signature plus an AI algorithm to classify transplant recipients into low- and high-risk categories for acute rejection, with the company also developing a 29-gene RNA-expression signature test, Clarava, for pre-transplant risk assessment. The company previously published validation data supporting the approach and noted Clarava is licensed to Thermo Fisher Scientific. With the New York decision removing a key barrier to broader use, Tutivia’s next step is payer coverage and uptake in transplant centers seeking earlier identification of rejection risk.